A rare CYP19 (aromatase) variant may increase the risk of breast cancer

被引:99
作者
Kristensen, VN
Andersen, TI
Lindblom, A
Erikstein, B
Magnus, P
Borresen-Dale, AL [1 ]
机构
[1] Norwegian Radium Hosp, Inst Canc Res, Dept Genet, N-0310 Oslo, Norway
[2] Karolinska Hosp, Dept Clin Genet, S-171176 Stockholm, Sweden
[3] Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[4] Natl Publ Hlth Inst, Dept Epidemiol, Oslo, Norway
来源
PHARMACOGENETICS | 1998年 / 8卷 / 01期
关键词
allele frequency; aromatase; bis-benzimide; breast cancer; CYP19; tetranucleotide repeat;
D O I
10.1097/00008571-199802000-00006
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The aromatase P450 (coded by the CYP19 gene) is responsible for the rate limiting step in the metabolism of C19 steroids to estrogens and is expressed in most breast carcinomas. A polymorphic tetranucleotide repeat (TTTA)(n) in intron 5, about 80 nucleotides downstream of exon 4 has previously been described. The allele frequencies of the polymorphic repeat were studied in series of 182 sporadic and 185 familial breast cancer patients as well as in 252 healthy control individuals. Five different alleles containing 7, 8, 9, 11 and 12-TTTA-repeats were detected. A relatively rare allele (Al) containing the longest repeat (TTTA)(12) was found significantly more frequently in breast cancer patients than in control individuals. This indicates that individuals carrying the Al allele of CYP19 may have an increased risk of developing breast cancer, OR 2.42 (95% confidence interval [CI] 1.03-5.80). The higher frequency was observed in both sporadic and familial patients, although when each of the groups was compared to the control group only a borderline significance was seen. A higher frequency of Al allele carriers was also found in the group of patients with positive estrogen receptor and progesterone receptor positive tumors. These data suggest that the CYP19 gene may be involved as a low penetrance gene in breast cancer susceptibility. (C) 1998 Chapman & Hall Ltd.
引用
收藏
页码:43 / 48
页数:6
相关论文
共 26 条
[1]  
ANDERSEN TI, 1994, HUM GENET, V94, P665
[2]  
ANDERSEN TI, 1997, IN PRESS HUM MUTATIO
[3]   CYP19 (AROMATASE CYTOCHROME-P450) GENE-EXPRESSION IN HUMAN-MALIGNANT ENDOMETRIAL TUMORS [J].
BULUN, SE ;
ECONOMOS, K ;
MILLER, D ;
SIMPSON, ER .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1994, 79 (06) :1831-1834
[4]   GENETIC-BASIS OF VARIABLE EXON-9 SKIPPING IN CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MESSENGER-RNA [J].
CHU, CS ;
TRAPNELL, BC ;
CURRISTIN, S ;
CUTTING, GR ;
CRYSTAL, RG .
NATURE GENETICS, 1993, 3 (02) :151-156
[5]  
EVANS CT, 1987, J BIOL CHEM, V262, P6914
[6]   Sequence-specific and length-dependent interaction of C2H2 zinc fingers and (TA)(n) microsatellites [J].
Gogos, JA ;
Karayiorgou, M .
HUMAN GENETICS, 1996, 98 (05) :616-619
[7]   TISSUE-SPECIFIC EXPRESSION OF THE HUMAN AROMATASE CYTOCHROME-P-450 GENE BY ALTERNATIVE USE OF MULTIPLE EXONS-1 AND PROMOTERS, AND SWITCHING OF TISSUE-SPECIFIC EXONS-1 IN CARCINOGENESIS [J].
HARADA, N ;
UTSUMI, T ;
TAKAGI, Y .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (23) :11312-11316
[8]   MOLECULAR AND EPIDEMIOLOGIC ANALYSES OF ABNORMAL EXPRESSION OF AROMATASE IN BREAST-CANCER [J].
HARADA, N ;
UTSUMI, T ;
TAKAGI, Y .
PHARMACOGENETICS, 1995, 5 :S59-S64
[9]  
HSU CL, 1991, J STEROID BIOCHEM, V87, P184
[10]   ESTROGEN AND ONCOGENE MEDIATED GROWTH-REGULATION OF HUMAN-BREAST CANCER-CELLS [J].
KASID, A ;
LIPPMAN, ME .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1987, 27 (1-3) :465-470